Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer

AbstractPurpose  Phenylacetate (PAA), a deaminated metabolite of phenylalanine, suppresses tumor growth and induces differentiation in preclinical tumor models. We performed a pharmacokinetic study, as part of a phase I trial, of PAA in children with refractory cancer.